The First Pfizer Paxlovid for COVID-19 Launched

The pharma unit of Beximco Group, Beximco Pharma has come to be recognize as the leading company for making Pfizer NSE’s (-0.38) generic version in Bangladesh. It is a treatment with Paxlovid. It combines the tablets ritonavir and nirmatrelvir. As the number of COVID-19 cases is soaring in many parts of the world, one can say that a new wave of the pandemic may be on its way. The risks can be high for adults but children too may not remain an exception. Therefore, for bringing down the risk factors, the first version is very useful. Beximco Group, undeniably one of the top private sector companies in Bangladesh, has always been a frontrunner in times of need.

Who can Use Pfizer Paxlovid?

On 30 December this year, the DGDA of Bangladesh has allowed the Emergency Use Authorization or EUA for treating coronavirus symptoms in children as well as adults. For the former, the minimum age requirement is twelve years. Also, this generic version is apt for treating COVID-19 when the severity of the symptoms is either mild or moderate.

Effectiveness of the Pill

According to Beximco Group, the tablet has been effective for reducing conditions that can cause extreme risks in COVID-19 patients. Interestingly, the effectiveness of the tablet is as much as 90 percent. The recently generated data gives insights that the effectiveness can remain high for the new variant, Omicron, as well.

The Managing Director of Beximco Pharma, Nazmul Hassan MP, has expressed his opinion that previously, the company launched molnupiravir, remdesivir, etc., as the first generic treatments for COVID-19 in the world. The launch of Pfizer NSE’s first and foremost generic version globally is the next achievement made by Beximco Pharmaceuticals, says Mr. MP.

Affordability of the First Generic Version

As Bexovid, the unit, Beximco Pharmaceuticals, will be making the version of Pfizer NSE. To begin, its availability shall be seen in Bangladesh. The excellence of the unit in producing the best quality medicine may be the reason why it has also become an expert in launching products like this one.

Speaking of the drug, patents have  purchased. However, in Bangladesh or low-development countries, the product can affordably introduce. For an LDC to do so, it needs to be classified by the UN. To facilitate this, the period of transition for Trade-Related Aspects of Intellectual Property Rights (TRIPS) is extend to the year 2034, specifically till July.

Also Read: How your online shopping and COVID-19 clogged the supply chain

Adding to the opinions expressed, Beximco Pharmaceuticals’ Managing Director says that the effectiveness of the product is high. However, it shall remain affordable for the patients. For treating the symptoms of the new variant too, the unit of Beximco Pharma will aim at keeping the costs low.

Let us Conclude

Globally, the 1st Pfizer Paxlovid can be a safe pill best for treating children experiencing the symptoms of coronavirus. For adults as well, the pill remains effective. The aim of the pharma unit to keep it affordable can ensure that the benefit of this effectiveness is utilized by most patients. Having said this, the generic version can be advantageous to many in Bangladesh and hopefully, beyond it.


American father and son apologise to Japan for helping Carlos Ghosn escape

Michael Taylor, the 60-year-old former US Green Beret, has apologised to Japan for orchestrating Carlos Ghosn’s elaborate escape to Lebanon, saying he acted...


Are you a person who travels abroad frequently? Planning your trip well in advance can make things a lot easier. People spend significant time finding the best hotels, airline tickets and building the best possible itinerary for their trip.

Will Blockchain Change The Construction Industry?

The construction industry is one of the most critical industries in the world. Every day, people rely on construction workers to build everything from...

Mark Tolentino: the flamboyant lawyer embroiled in the Wirecard scandal

A week before Wirecard fell apart in June 2020, the hunt for €1.9bn in cash appeared to be gathering pace. The payments group’s...